Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
February 27, 2023 16:05 ET
|
Portage Biotech, Inc.
Targeting Adenosine for Cancer:Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9th @ 10:30 am ET WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) --...
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
February 15, 2023 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and...
Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
November 29, 2022 16:43 ET
|
Portage Biotech, Inc.
--Updated Data on Phase 1/2 Trial Evaluating PORT-2 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting-- --Clinical Collaboration Agreement Entered into with Merck for...
Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 09:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival,...
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
November 08, 2022 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient...
Portage Biotech Provides Research and Development Update
September 14, 2022 08:39 ET
|
Portage Biotech, Inc.
--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types...
Portage Biotech to Present at Upcoming Investor Conferences
September 08, 2022 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival,...
Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
August 29, 2022 08:00 ET
|
Portage Biotech, Inc.
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New...
Portage Biotech Announces Leadership Updates
August 18, 2022 08:00 ET
|
Portage Biotech, Inc.
CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild, MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT,...
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
August 01, 2022 09:10 ET
|
Portage Biotech, Inc.
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage...